BGI
Although demand for the firm's COVID-19 testing declined in H1, other diagnostic areas and its international business have grown.
Labs and commercial developers have created simple, inexpensive PCR assays for the SARS-CoV-2 Delta variant that they say could help surveillance efforts.
BGI Genomics H1 Revenues Fall 11 Percent on COVID-19 Testing Decline
The firm's other businesses saw steady growth, with cancer prevention revenues up 94 percent and infection prevention and control revenues more than tripling.
Since the proteomics facility launched in 2019, revenues have roughly doubled each year and it has doubled its staff, with biopharma driving much of the demand.